$CRSP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in CRISPR Therapeutics AG.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in CRISPR Therapeutics AG. Get notifications about new insider transactions in CRISPR Therapeutics AG for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 12.57 | 30,000 | 377,100 | 63,333 | |
Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 127.51 | 3,488 | 444,755 | 187,719 | 191.2 K to 187.7 K (-1.82 %) |
Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 126.86 | 16,129 | 2,046,125 | 191,207 | 207.3 K to 191.2 K (-7.78 %) |
Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 125.39 | 10,383 | 1,301,924 | 207,336 | 217.7 K to 207.3 K (-4.77 %) |
Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 12.57 | 30,000 | 377,100 | 217,719 | 187.7 K to 217.7 K (+15.98 %) |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 44.67 | 12,000 | 536,040 | 43,000 | |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 40.87 | 20,000 | 817,400 | 25,000 | |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 29.87 | 10,000 | 298,700 | 10,000 | |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 51.49 | 22,000 | 1,132,780 | 38,000 | |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 17.66 | 12,000 | 211,920 | 3,000 | |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 14.43 | 12,000 | 173,160 | 2,666 | |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 126.97 | 12,000 | 1,523,640 | 1,050 | 13.1 K to 1.1 K (-91.95 %) |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 128.20 | 88,000 | 11,281,600 | 13,050 | 101.1 K to 13.1 K (-87.09 %) |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 17.66 | 12,000 | 211,920 | 101,050 | 89.1 K to 101.1 K (+13.48 %) |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 14.43 | 12,000 | 173,160 | 89,050 | 77.1 K to 89.1 K (+15.57 %) |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 40.87 | 20,000 | 817,400 | 77,050 | 57.1 K to 77.1 K (+35.06 %) |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 29.87 | 10,000 | 298,700 | 57,050 | 47.1 K to 57.1 K (+21.25 %) |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 51.49 | 22,000 | 1,132,780 | 47,050 | 25.1 K to 47.1 K (+87.82 %) |
Mar 25 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 44.67 | 12,000 | 536,040 | 25,050 | 13.1 K to 25.1 K (+91.95 %) |
Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 134.93 | 300 | 40,478 | 30,375 | 30.7 K to 30.4 K (-0.98 %) |
Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 134.33 | 5,237 | 703,495 | 30,675 | 35.9 K to 30.7 K (-14.58 %) |
Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 133.28 | 9,334 | 1,244,070 | 35,912 | 45.2 K to 35.9 K (-20.63 %) |
Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 132.53 | 6,090 | 807,092 | 45,246 | 51.3 K to 45.2 K (-11.86 %) |
Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 131.14 | 2,400 | 314,741 | 51,336 | 53.7 K to 51.3 K (-4.47 %) |
Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 130.42 | 3,413 | 445,112 | 53,736 | 57.1 K to 53.7 K (-5.97 %) |
Mar 24 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 129.36 | 3,600 | 465,678 | 57,149 | 60.7 K to 57.1 K (-5.93 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 0.00 | 9,000 | 0 | 9,000 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 133.88 | 25,360 | 3,395,197 | 25,360 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Payment of Exercise | F | 124.15 | 1,352 | 167,851 | 1,891 | 3.2 K to 1.9 K (-41.69 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Buy | M | 0.00 | 2,833 | 0 | 3,243 | 410 to 3.2 K (+690.98 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 0.00 | 36,000 | 0 | 36,000 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 133.88 | 100,000 | 13,388,000 | 100,000 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 124.15 | 5,526 | 686,053 | 188,498 | 194 K to 188.5 K (-2.85 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 0.00 | 11,833 | 0 | 194,024 | 182.2 K to 194 K (+6.49 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | A | 0.00 | 12,000 | 0 | 12,000 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | A | 133.88 | 33,334 | 4,462,756 | 33,334 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Payment of Exercise | F | 124.15 | 2,141 | 265,805 | 13,050 | 15.2 K to 13.1 K (-14.09 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 0.00 | 4,583 | 0 | 15,191 | 10.6 K to 15.2 K (+43.20 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Option Exercise | A | 0.00 | 9,000 | 0 | 9,000 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Option Exercise | A | 133.88 | 25,360 | 3,395,197 | 25,360 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Payment of Exercise | F | 124.15 | 1,353 | 167,975 | 23,911 | 25.3 K to 23.9 K (-5.36 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Buy | M | 0.00 | 2,833 | 0 | 25,264 | 22.4 K to 25.3 K (+12.63 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Option Exercise | A | 0.00 | 9,000 | 0 | 9,000 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Option Exercise | A | 133.88 | 23,334 | 3,123,956 | 23,334 | |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Payment of Exercise | F | 124.15 | 2,141 | 265,805 | 38,304 | 40.4 K to 38.3 K (-5.29 %) |
Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Buy | M | 0.00 | 4,583 | 0 | 40,445 | 35.9 K to 40.4 K (+12.78 %) |
Mar 09 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Payment of Exercise | F | 114.65 | 1,585 | 181,720 | 35,862 | 37.4 K to 35.9 K (-4.23 %) |
Mar 09 2021 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Buy | M | 0.00 | 3,333 | 0 | 37,447 | 34.1 K to 37.4 K (+9.77 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 565 | 0 | 60,749 | 60.2 K to 60.7 K (+0.94 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 4,012 | 0 | 0 | 4 K to 0 (-100.00 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 4,012 | 0 | 4,012 | 0 to 4 K |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 18,574 | 0 | 44,295 | 62.9 K to 44.3 K (-29.54 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 12,648 | 0 | 60,184 | 47.5 K to 60.2 K (+26.61 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 56,056 | 0 | 0 | 56.1 K to 0 (-100.00 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 1,755 | 0 | 56,056 | 54.3 K to 56.1 K (+3.23 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 8,126 | 0 | 18,457 | 26.6 K to 18.5 K (-30.57 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 1,585 | 0 | 54,301 | 52.7 K to 54.3 K (+3.01 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 7,341 | 0 | 16,625 | 24 K to 16.6 K (-30.63 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 52,716 | 0 | 52,716 | 0 to 52.7 K |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 244,056 | 0 | 581,999 | 826.1 K to 582 K (-29.54 %) |
Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 130.25 | 798 | 103,940 | 182,191 | 183 K to 182.2 K (-0.44 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 20,000 | 36,200 | 108,983 | |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 217.44 | 1,304 | 283,542 | 182,989 | 184.3 K to 183 K (-0.71 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 216.50 | 1,708 | 369,782 | 184,293 | 186 K to 184.3 K (-0.92 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 214.68 | 1,700 | 364,956 | 186,001 | 187.7 K to 186 K (-0.91 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 213.71 | 5,623 | 1,201,691 | 187,701 | 193.3 K to 187.7 K (-2.91 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 212.75 | 6,525 | 1,388,194 | 193,324 | 199.8 K to 193.3 K (-3.26 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 211.83 | 3,140 | 665,146 | 199,849 | 203 K to 199.8 K (-1.55 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 20,000 | 36,200 | 202,989 | 183 K to 203 K (+10.93 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 14.43 | 16,334 | 235,700 | 14,666 | |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Option Exercise | M | 12.57 | 8,666 | 108,932 | 0 | |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 219.99 | 2 | 440 | 20,000 | 20 K to 20 K (-0.01 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 218.54 | 701 | 153,197 | 20,002 | 20.7 K to 20 K (-3.39 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 217.42 | 9,997 | 2,173,548 | 20,703 | 30.7 K to 20.7 K (-32.56 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 216.39 | 1,500 | 324,585 | 30,700 | 32.2 K to 30.7 K (-4.66 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 214.60 | 700 | 150,220 | 32,200 | 32.9 K to 32.2 K (-2.13 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 213.64 | 2,800 | 598,192 | 32,900 | 35.7 K to 32.9 K (-7.84 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 212.20 | 634 | 134,535 | 35,700 | 36.3 K to 35.7 K (-1.74 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 14.43 | 16,344 | 235,844 | 36,334 | 20 K to 36.3 K (+81.76 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 217.45 | 200 | 43,490 | 20,000 | 20.2 K to 20 K (-0.99 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 216.24 | 400 | 86,496 | 20,200 | 20.6 K to 20.2 K (-1.94 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 214.46 | 1,400 | 300,244 | 20,600 | 22 K to 20.6 K (-6.36 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 213.71 | 1,200 | 256,452 | 22,000 | 23.2 K to 22 K (-5.17 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 212.54 | 2,555 | 543,040 | 23,200 | 25.8 K to 23.2 K (-9.92 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Sell | S | 211.44 | 2,911 | 615,502 | 25,755 | 28.7 K to 25.8 K (-10.15 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Buy | M | 12.57 | 8,666 | 108,932 | 28,666 | 20 K to 28.7 K (+43.33 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Option Exercise | M | 51.49 | 27,500 | 1,415,975 | 12,500 | |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Sell | S | 207.61 | 2,100 | 435,981 | 22,431 | 24.5 K to 22.4 K (-8.56 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Sell | S | 206.05 | 1,800 | 370,890 | 24,531 | 26.3 K to 24.5 K (-6.84 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Sell | S | 205.60 | 8,997 | 1,849,783 | 26,331 | 35.3 K to 26.3 K (-25.47 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Sell | S | 204.40 | 7,818 | 1,597,999 | 35,328 | 43.1 K to 35.3 K (-18.12 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Sell | S | 203.58 | 6,785 | 1,381,290 | 43,146 | 49.9 K to 43.1 K (-13.59 %) |
Jan 20 2021 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Buy | M | 51.49 | 27,500 | 1,415,975 | 49,931 | 22.4 K to 49.9 K (+122.60 %) |
Jan 04 2021 | CRSP | CRISPR Therapeutic ... | Klein Lawrence Otto | CBO & COO | Payment of Exercise | F | 153.11 | 9,392 | 1,438,009 | 10,608 | 20 K to 10.6 K (-46.96 %) |
Dec 30 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 13,800 | 24,978 | 128,983 | |
Dec 30 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 13,800 | 24,978 | 182,989 | 169.2 K to 183 K (+8.16 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Option Exercise | M | 16.90 | 23,551 | 398,012 | 236,449 | |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Sell | S | 150.61 | 2,951 | 444,450 | 33,964 | 36.9 K to 34 K (-7.99 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Sell | S | 149.73 | 5,000 | 748,650 | 36,915 | 41.9 K to 36.9 K (-11.93 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Sell | S | 148.38 | 8,400 | 1,246,392 | 41,915 | 50.3 K to 41.9 K (-16.69 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Sell | S | 147.05 | 1,400 | 205,870 | 50,315 | 51.7 K to 50.3 K (-2.71 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Sell | S | 152.41 | 500 | 76,205 | 51,715 | 52.2 K to 51.7 K (-0.96 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Sell | S | 151.58 | 1,100 | 166,738 | 52,215 | 53.3 K to 52.2 K (-2.06 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Sell | S | 150.16 | 1,600 | 240,256 | 53,315 | 54.9 K to 53.3 K (-2.91 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Sell | S | 149.18 | 900 | 134,262 | 54,915 | 55.8 K to 54.9 K (-1.61 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Sell | S | 148.11 | 1,700 | 251,787 | 55,815 | 57.5 K to 55.8 K (-2.96 %) |
Dec 22 2020 | CRSP | CRISPR Therapeutic ... | Ho Tony W | Executive VP, Head ... | Buy | M | 16.90 | 23,551 | 398,012 | 57,515 | 34 K to 57.5 K (+69.34 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 151.05 | 931 | 140,625 | 339,834 | 340.8 K to 339.8 K (-0.27 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 151.05 | 969 | 146,365 | 0 | 969 to 0 (-100.00 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 150.14 | 958 | 143,837 | 340,765 | 341.7 K to 340.8 K (-0.28 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 150.14 | 995 | 149,392 | 969 | 2 K to 969 (-50.66 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 149.12 | 2,009 | 299,586 | 341,723 | 343.7 K to 341.7 K (-0.58 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 149.12 | 2,091 | 311,815 | 1,964 | 4.1 K to 2 K (-51.57 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 148.28 | 2,576 | 381,972 | 343,732 | 346.3 K to 343.7 K (-0.74 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 148.28 | 2,679 | 397,245 | 4,055 | 6.7 K to 4.1 K (-39.78 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 147.00 | 878 | 129,068 | 346,308 | 347.2 K to 346.3 K (-0.25 %) |
Dec 18 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 147.00 | 914 | 134,360 | 6,734 | 7.6 K to 6.7 K (-11.95 %) |
Dec 14 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 144.85 | 15,900 | 2,303,155 | 314,186 | 330.1 K to 314.2 K (-4.82 %) |
Dec 14 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 143.26 | 2,223 | 318,462 | 330,086 | 332.3 K to 330.1 K (-0.67 %) |
Dec 14 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 142.42 | 5,958 | 848,562 | 332,309 | 338.3 K to 332.3 K (-1.76 %) |
Dec 14 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 141.54 | 6,648 | 940,923 | 338,267 | 344.9 K to 338.3 K (-1.93 %) |
Dec 14 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | S | 140.62 | 2,271 | 319,345 | 344,915 | 347.2 K to 344.9 K (-0.65 %) |
Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 20,000 | 36,200 | 142,783 | |
Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 144.97 | 600 | 86,982 | 169,189 | 169.8 K to 169.2 K (-0.35 %) |
Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 143.71 | 2,100 | 301,791 | 169,789 | 171.9 K to 169.8 K (-1.22 %) |
Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 142.75 | 6,766 | 965,847 | 171,889 | 178.7 K to 171.9 K (-3.79 %) |
Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 141.98 | 5,034 | 714,727 | 178,655 | 183.7 K to 178.7 K (-2.74 %) |
Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 141.17 | 5,500 | 776,435 | 183,689 | 189.2 K to 183.7 K (-2.91 %) |
Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 20,000 | 36,200 | 189,189 | 169.2 K to 189.2 K (+11.82 %) |
Dec 10 2020 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Option Exercise | M | 13.62 | 22,026 | 299,994 | 100,974 | |
Dec 10 2020 | CRSP | CRISPR Therapeutic ... | KASINGER JAMES R. | General Counsel and ... | Buy | M | 13.62 | 22,026 | 299,994 | 22,415 | 389 to 22.4 K (+5,662.21 %) |
Dec 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 129.58 | 779 | 100,943 | 169,189 | 170 K to 169.2 K (-0.46 %) |
Dec 02 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Option Exercise | M | 14.43 | 50,000 | 721,500 | 140,315 | |
Dec 02 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Option Exercise | M | 14.00 | 50,000 | 700,000 | 61,893 | |
Dec 02 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Sell | S | 125.00 | 50,000 | 6,250,000 | 648,007 | 698 K to 648 K (-7.16 %) |
Dec 02 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Buy | M | 14.43 | 50,000 | 721,500 | 698,007 | 648 K to 698 K (+7.72 %) |
Dec 02 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Sell | S | 125.00 | 50,000 | 6,250,000 | 648,007 | 698 K to 648 K (-7.16 %) |
Dec 02 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Buy | M | 14.00 | 50,000 | 700,000 | 698,007 | 648 K to 698 K (+7.72 %) |
Nov 02 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 18,477 | 0 | 40,648 | 22.2 K to 40.6 K (+83.34 %) |
Nov 02 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 2,433 | 0 | 7,922 | 10.4 K to 7.9 K (-23.50 %) |
Nov 02 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 105,681 | 0 | 0 | 105.7 K to 0 (-100.00 %) |
Nov 02 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Buy | J | 0.00 | 105,681 | 0 | 105,681 | 0 to 105.7 K |
Nov 02 2020 | CRSP | CRISPR Therapeutic ... | Bolzon Bradley J PhD | Director | Sell | J | 0.00 | 410,405 | 0 | 1,336,088 | 1.7 M to 1.3 M (-23.50 %) |
Oct 13 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Option Exercise | M | 14.43 | 2,762 | 39,856 | 190,315 | |
Oct 13 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Option Exercise | M | 14.43 | 22,238 | 320,894 | 193,077 | |
Oct 13 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Sell | S | 100.00 | 2,762 | 276,200 | 648,007 | 650.8 K to 648 K (-0.42 %) |
Oct 13 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Buy | M | 14.43 | 2,762 | 39,856 | 650,769 | 648 K to 650.8 K (+0.43 %) |
Oct 13 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Sell | S | 100.00 | 22,238 | 2,223,800 | 648,007 | 670.2 K to 648 K (-3.32 %) |
Oct 13 2020 | CRSP | CRISPR Therapeutic ... | Novak Rodger | President | Buy | M | 14.43 | 22,238 | 320,894 | 670,245 | 648 K to 670.2 K (+3.43 %) |
Oct 06 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 86.75 | 11,666 | 1,012,026 | 11,666 |